| Name | Title | Contact Details |
|---|
The pioneering team at Surefire Medical is inventing the future for cancer care. We develop advanced liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries paired with new, precise technology arm physicians to harness infusion pressure and work with the body’s natural flow, targeting tumors with superior accuracy, control and protection. Our founders, a biomedical engineer and an Interventional Radiologist, established Surefire Medical to revolutionize cancer treatment. Our inventive device technology is designed by and for the IR community by a Colorado-based team of physicians, engineers and researchers. We seek clinical discoveries and create new technologies with one goal in mind: to deliver improved outcomes for cancer patients and their families.
Belmont Instruments is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardon Outreach works tirelessly to reduce the financial burden of medical bills on Americans and on the healthcare providers who serve them. Our work makes a positive difference to thousands of people and hundreds of hospitals and clinics, in communities all over the nation, every day. It is this mission that enables our success at over 800 facilities across 39 states. Over our 20+ years of service we have helped over 24 million individuals, translating into over $100 billion dollars in healthcare spend. Our technology driven, innovative approach to the revenue cycle is prepared to overcome the challenges of the Affordable Care Act. Through our approach to hiring and developing the right people and our sophisticated proprietary technology, MPower, we improve the patient experience, improve your facility`s reputation, reduce A/R days, increase cash-on-hand, and provide on demand proof-of-compliance.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
Founded in 1985, Axelgaard Manufacturing Co., Ltd. (AMC) has grown to become the premier manufacturer of neurostimulation electrodes. Our primary brand is our patented PALS Neurostimulation Electrodes. We are dedicated to providing the highest quality